SVB Leerink reiterated coverage on Atea Pharmaceuticals with a new price target

10/20/21 9:15:33 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

SVB Leerink reiterated coverage of Atea Pharmaceuticals with a rating of Outperform and set a new price target of $20.00 from $60.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$AVIR

Date	Price Target	Rating	Analyst
8/13/2024	$2.00 → $6.88	Underweight → Equal-Weight	Morgan Stanley
8/10/2023		Neutral → Underweight	JP Morgan
3/2/2022	$10.00 → $8.00	Neutral	JP Morgan
3/1/2022	$10.00 → $9.00	Market Perform	SVB Leerink
2/16/2022	$11.00 → $10.00	Market Perform	SVB Leerink
1/6/2022	$14.00 → $7.00	Equal-Weight → Underweight	Morgan Stanley
11/18/2021		Outperform → Mkt Perform	SVB Leerink
11/18/2021	$11.00	Outperform → Market Perform	SVB Leerink